Filing Flows › IGC Pharma (IGC) › Q1 2025
IGC Pharma (IGC) Q1 2025 earnings results (first quarter 2025)
10-K filed Jun 27, 2025
IGC Pharma (IGC) reported revenue of $330K for the first quarter 2025 (Q1 2025), +12% from a year earlier and +28% from the quarter before. Operating margin was -428.2%, net loss $1.2M (363.0% of revenue).
IGC Pharma, Q1 2025: revenue $330K (+12% year over year), operating margin -428.2%, net loss $1.2M, operating cash flow −$730K. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $330K | +28% | +12% |
| Operating profit | −$1.4M | — | — |
| Net earnings | −$1.2M | — | — |
| Operating cash flow | −$730K | — | — |
What changed
Revenue was $330K in Q1 2025, up 12% year over year and up 28% from the previous quarter.
Gross margin was 46.7%, down 11.3 points from a year earlier. Operating costs exceeded revenue by $1.4M, an operating margin of -428.2%. Operating expenses fell 33% while revenue rose 12%. The fastest-growing cost line was Research & development (+17%). The quarter ended with a net loss of $1.2M, narrower than the previous quarter's $1.8M loss.
Operating cash flow was −$730K. Non-cash charges added back $154K of depreciation and amortization. Working capital and other items added $314K. Capital expenditures of $18K exceeded it, leaving free cash flow of −$748K.
Questions
What was IGC Pharma's revenue in the first quarter 2025?
IGC Pharma (IGC) reported revenue of $330K for the first quarter 2025 (Q1 2025), +12% from a year earlier and +28% from the quarter before.
Was IGC Pharma profitable in the first quarter 2025?
Operating loss was $1.4M (-428.2% of revenue) and net loss $1.2M.
Source: IGC Pharma 10-K on SEC EDGAR.